Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Myriad Genetics Partners with GSK to Enhance HRD Testing Accessibility Across Nine Nations

NextEdge Admin

12 Jun 2024

2 min 15 sec

Myriad Genetics, has entered into a collaboration with GSK to broaden access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients. Through this partnership, a sponsored testing program employing Myriad’s MyChoice HRD Plus and MyChoice CDx Plus Tests is being introduced across several countries, including Argentina, Brazil, and the United Arab Emirates. These tests serve a critical role in identifying HRD status, equipping clinicians with valuable information to make personalized treatment decisions for individuals battling ovarian cancer.

The collaboration between Myriad Genetics and GSK aims to address the pressing need for accessible testing solutions in underserved markets, ensuring that patients, regardless of their geographic location, can benefit from advanced genetic insights. Patrick Burke, the Executive Vice President of Strategy and Innovation at Myriad Genetics, highlighted the significance of this collaboration in advancing healthcare equity and extending the reach of diagnostic solutions to support tailored patient care based on individual genomic profiles.

Myriad’s MyChoice Test stands out as the most comprehensive tumor test available, offering a detailed analysis of genomic alterations, including in genes such as BRCA1 and BRCA2, alongside the Genomic Instability Score (GIS) status determined through a proprietary algorithm. This depth of analysis enables healthcare professionals to identify patients who are more likely to respond to treatment with targeted therapies, thereby improving treatment outcomes and patient quality of life.